9005-35-0 Usage
Uses
Used in Wound Care:
Calcium alginate is used as a wound dressing for moderate to heavily exudative wounds during the transition from debridement to repair phase of wound healing. It is particularly useful for slow healing wounds like leg ulcers, which can continue to bleed and weep for a long time. The dressings release calcium ions in exchange for sodium ions upon contact with blood, which can help the blood to clot and encourage healing. Calcium alginate dressings with silver have been found to be safe and effective for use for leg ulcers.
Used in Cosmetics:
Calcium alginate is used as a visual accent in cosmetics. It is an alginate gel impregnated with an oily core material that can be pigmented or neutral in color. It can also be used to mask odor and adjust product viscosity.
Used in Food Industry:
Calcium alginate functions as a stabilizer and thickener. The partial obtainment of calcium alginate by the reaction of the water-soluble alginate with calcium ions is used to obtain viscosity and gel formation. It is used in icings, imitation pulp, dessert gels, and fabricated fruits.
Used in Medicines and Dental Impression Materials:
Calcium alginate is used in various applications in the medical and dental fields, including as a component in medicines and dental impression materials. Its properties make it suitable for these applications, where it can provide structural support and help in the formation of gels and other structures.
Production Methods
Calcium alginate can be obtained from seaweed, mainly species of
Laminaria.
Solutions of sodium alginate interact with an ionized calcium
salt, resulting in the instantaneous precipitation of insoluble calcium
alginate, which can then be further processed. Introducing varying
proportions of sodium ions during manufacture can produce
products having different absorption rates.
Pharmaceutical Applications
In pharmaceutical formulations, calcium alginate and calciumsodium
alginate have been used as tablet disintegrants. The use of
a high concentration (10%) of calcium-sodium alginate has been
reported to cause slight speckling of tablets.
A range of different types of delivery systems intended for oral
administration have been investigated. These exploit the gelling
properties of calcium alginate. Calcium alginate beads have been
used to prepare floating dosage systems containing amoxicillin, furosemide, meloxicam, and barium sulfate,(10) and as a
means of providing a sustained or controlled-release action for
sulindac, diclofenac, tiaramide, insulin, and ampicillin. The effect of citric acid in prolonging the gastric retention
of calcium alginate floating dosage forms has been reported.
Impregnating meloxicam in calcium alginate beads may reduce the
risk of ulceration and mucosal inflammation following oral
adminstration. The use of calcium alginate beads, reinforced
with chitosan, has been shown to slow the release of verapamil,
and may be useful for the controlled release of protein drugs to the
gastrointestinal tract. The bioadhesive properties, swelling
and drug release of calcium alginate beads have also been
investigated.
A series of studies investigating the production, formulation,) and drug release from calcium alginate matrices for oral
administration have been published. The release of diltiazem
hydrochloride from a polyvinyl alcohol matrix was shown to be
controlled by coating with a calcium alginate membrane; the drug
release profile could be modified by increasing the coating thickness
of the calcium alginate layer. The microencapsulation of live
attenuated Bacillus Calmette–Guerin (BCG) cells within a calcium
alginate matrix has also been reported.
It has been shown that a modified drug release can be obtained
from calcium alginate microcapsules, pellets, and microspheres. When biodegradable bone implants composed of
calcium alginate spheres and containing gentamicin were introduced
into the femur of rats, effective drug levels in bone and soft
tissue were obtained for 30 days and 7 days, respectively. The
incorporation of radioactive particles into calcium alginate gels may
be useful for the localized delivery of radiation therapy to a wide
range of organs and tissues.
Therapeutically, the gelling properties of calcium alginate are
utilized in wound dressings in the treatment of leg ulcers, pressure
sores, and other exuding wounds. These dressings are highly
absorbent and are suitable for moderately or heavily exuding
wounds. Calcium alginate dressings also have hemostatic properties,
with calcium ions being exchanged for sodium ions in the
blood; this stimulates both platelet activation and whole blood
coagulation. A mixed calcium–sodium salt of alginic acid is used as
fibers in dressings or wound packing material.
Sterile powder consisting of a mixture of calcium and sodium
alginates has been used in place of talc in glove powders.
In foods, calcium alginate is used as an emulsifier, thickener, and
stabilizer.
Safety Profile
Poison by intravenous
route. Moderately toxic by intraperitoneal route. When heated to decomposition it
emits acrid smoke and irritating fumes.
Safety
Calcium alginate is widely used in oral and topical formulations,
and in foods.
In 1974, the WHO set an estimated acceptable daily intake of
calcium alginate of up to 25 mg, as alginic acid, per kilogram bodyweight.
When heated to decomposition, it emits acrid smoke and
irritating fumes.
LD50 (rat, IP): 1.41 g/kg
LD50 (rat, IV): 0.06 g/kg
storage
Calcium alginate can be sterilized by autoclaving at 1158℃ for 30
minutes or by dry heat at 1508℃ for 1 hour. Calcium alginate should
be stored in airtight containers.
Incompatibilities
Calcium alginate is incompatible with alkalis and alkali salts.
Propranolol hydrochloride has been shown to bind to alginate
molecules, suggesting that propranolol and calcium ions share
common binding sites in the alginate chains; the formation of the
calcium alginate gel structure was impeded in the presence of
propranolol molecules.
Regulatory Status
GRAS listed. Accepted for use as a food additive in Europe.
Included in the FDA Inactive Ingredients Database (oral tablets).
Included in nonparenteral medicines licensed in the UK.
Check Digit Verification of cas no
The CAS Registry Mumber 9005-35-0 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 9,0,0 and 5 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 9005-35:
(6*9)+(5*0)+(4*0)+(3*5)+(2*3)+(1*5)=80
80 % 10 = 0
So 9005-35-0 is a valid CAS Registry Number.
InChI:InChI=1/C18H26O19.Ca/c19-1-2(20)10(13(26)27)36-17(6(1)24)35-9-4(22)7(25)18(37-12(9)15(30)31)34-8-3(21)5(23)16(32)33-11(8)14(28)29;/h1-12,16-25,32H,(H,26,27)(H,28,29)(H,30,31);/q;+2/p-2/t1-,2-,3+,4+,5-,6-,7-,8-,9-,10-,11+,12+,16+,17+,18+;/m0./s1
